MDxHealth SA (NASDAQ:MDXH) Sees Large Decline in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 15,027 shares, a decrease of 42.6% from the November 30th total of 26,198 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Institutional Trading of MDxHealth

Hedge funds have recently modified their holdings of the stock. AWM Investment Company Inc. boosted its holdings in MDxHealth by 10.6% during the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock worth $7,414,000 after buying an additional 499,992 shares during the last quarter. FreeGulliver LLC bought a new stake in shares of MDxHealth in the 2nd quarter valued at about $273,000. Calamos Advisors LLC acquired a new stake in shares of MDxHealth in the 3rd quarter valued at approximately $305,000. GSA Capital Partners LLP bought a new position in MDxHealth during the 3rd quarter worth approximately $48,000. Finally, Jefferies Financial Group Inc. bought a new position in MDxHealth during the 3rd quarter worth approximately $53,000.

MDxHealth Price Performance

NASDAQ MDXH traded down $0.06 during trading on Monday, reaching $3.35. 98,374 shares of the company traded hands, compared to its average volume of 124,809. MDxHealth has a 1-year low of $1.35 and a 1-year high of $5.33. The company has a market cap of $158.41 million, a price-to-earnings ratio of -5.23 and a beta of 1.59. The stock’s 50 day moving average price is $3.84 and its two-hundred day moving average price is $3.38. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.02 and a current ratio of 1.14.

MDxHealth (NASDAQ:MDXH) last issued its earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $27.43 million during the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. As a group, analysts anticipate that MDxHealth will post -1.15 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MDXH. TD Cowen boosted their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. BTIG Research restated a “buy” rating and set a $7.00 price target on shares of MDxHealth in a research note on Tuesday, December 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of MDxHealth in a research report on Wednesday, October 8th. Finally, Lake Street Capital lifted their price objective on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.